Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens

BMC Infectious Diseases

Volumn 5, Issue , 2005, Pages

  Swindells, Susan ^a   Cohen, Calvin J ^b   Berger, Daniel S ^c   Tashima, Karen T ^d   Liao, Qiming ^e   Pobiner, Bonnie F ^e   Snidow, Jerry W ^e   Pakes, Gary E ^e   Hernandez, Jaime E ^e   Becker, Stephen ^f   Pearce, Daniel ^g   Woodward, William C ^h   Paar, David ⁱ   Cooley, Timothy P ^j   Seekins, Daniel ^k   Eron, Joe ^l   Green, Stephen ^m   Mildvan, Donna ⁿ   Schleupner, Charles ^o   Richmond, Gary ^p  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Boston Community Research Initiative of New England   (United States)

^c Northstar Medical Center   (United States)

^d MIRIAM HOSPITAL   (United States)

^e GLAXOSMITHKLINE   (United States)

^f Pacific Horizon Medical Group   (United States)

^g St Luke Medical Group   (United States)

^h Anderson Clinical Research   (United States)

ⁱ UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^j BOSTON MEDICAL CENTER   (United States)

^k St Joseph's Comprehensive Research Center   (United States)

^l UNIVERSITY OF NORTH CAROLINA   (United States)

^m Hampton Roads Medical Specialists   (United States)

ⁿ BETH ISRAEL MEDICAL CENTER   (United States)

^o NEW HANOVER REGIONAL MEDICAL CENTER   (United States)

^p Broward General Medical Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; AMPRENAVIR; AMYLASE; CREATINE KINASE; DIDANOSINE; DROXIA; EFAVIRENZ; GLUCOSE; HYDROXYUREA; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL; VIRUS RNA; ZALCITABINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; OXAZINE DERIVATIVE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ANOREXIA; ANTIVIRAL ACTIVITY; APPENDICITIS; ARTHRALGIA; ARTICLE; ASPHYXIA; BLOOD TOXICITY; BODY WEIGHT DISORDER; BRONCHITIS; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DIZZINESS; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR NOSE THROAT DISEASE; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERAMYLASEMIA; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALAISE; MALE; MEMORY DISORDER; MULTICENTER STUDY; NAIL DISEASE; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NOSE DISEASE; OPEN STUDY; PANCREATITIS; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP DISORDER; STATISTICAL ANALYSIS; TREATMENT FAILURE; UNPLEASANT DREAM; VOMITING; BLOOD; CD4 LYMPHOCYTE COUNT; COMPARATIVE STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; MIDDLE AGED; PHASE 4 CLINICAL TRIAL; TIME;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DIDEOXYNUCLEOSIDES; FEMALE; HIV INFECTIONS; HUMANS; HYDROXYUREA; MALE; MIDDLE AGED; OXAZINES; RNA, VIRAL; TIME FACTORS; TREATMENT FAILURE;

EID: 25444507990     PISSN: 14712334     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-5-23     Document Type: Article

References (38)

1. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA, Deutsch P, Holder D, Schleif WA, Condra JH: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
2. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Feinberg JE, Balfour HH, Deyton LR, Chodakewitz JA, Fischl MA, Phair JP, Pedneault L, Nguyen B-Y, Cook JC, for The AIDS Clinical Trials Group 320 Study Team: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
3. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F: Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS 2001, 15:1369-1377.
4. Opravil M, Hirschel B, Lazzarin A, Furrer H, Chave J-P, Yerly S, Bisset LR, Fischer M, Vernazza P, Bernasconi E, Battegay M, Ledergerber B, Günthard H, Howe C, Weber R, Perrin L, for the Swiss HIV Cohort Study: A randomized trial of simplified mantenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002, 185:1251-1260.
5. Katlama C, Fenske S, Gazzard B, Lazzarin A, Clumeck N, Mallolas J, Lafeuillade A, Mamet J-P, Beauvais L, on behalf of the AZL30002 European study team: TRIZAL study: switching from successful HAART to Trizivir™ (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med 2003, 4:79-86.
6. Clumeck N, Goebel F, Rozenbaum W, Gerstoft J, Staszewski S, Montaner J, Johnson M, Gazzard B, Stone C, Athisegaran R, Moore S, on behalf of the CNA30017 Study Team: Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001, 15:1517-1526.
7. Pulvirenti J, Goodwin D, Slater L, Rodriguez A, Fleming J, Williams V, Kauf T, Hernandez J: Simplification of protease inhibitor (PI)-containing HAART regimens with abacavir (ABC) maintains viral suppression and favorable adherence in HIV-1-infected adults (COL30305). 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco, California. Poster 689. October 25-28, 2001
8. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ, Ruiz NM, for The Study 006 Team: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999, 341:1865-1873.
9. Hirschel B, Flepp M, Bucher H, Heiner C, Zellweger C, Telenti A, Wagels T, Bernasconi E, Ledergerber B, the Swiss HIV Cohort: Switching from protease inhibitors to efavirenz: difference in efficacy and tolerance among risk groups: a case:control study from the Swiss HIV Cohort. AIDS 2002, 16:381-385.
10. Lori F, Malykh A, Cara A, Sun D, Weinstein JN, Lisziewicz J, Gallo RC: Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994, 266:801-805.
11. Bianchi V, Borrella S, Calderazzo F, Ferraro P, Chieco Bianchi L, Reichard P: Inhibition of ribonucleotide reductase by 2-substituted deoxycytidine analogs: possible application in AIDS treatment. Proc Natl Acad Sci USA 1994, 91:8403-8407.
12. Sumpter LR, Inayat MS, Elford HL, Gallicchio VS: Novel ribonucleotide reductase inhibitors (RRIs) trimidox (TX), didox (DX) and hydroxyurea (HU) enhance the anti-viral activity of abacavir (ABC) in vivo. XIV International AIDS Conference, Barcelona, Spain. Abstract A10131. July 7-12, 2002
13. Foli A, Lori F, Maserati R, Tinelli C, Minoli L, Lisziewicz J: Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine. Antivir Ther 1997, 2:31-38.
14. Lori F, Rosenberg E, Lieberman J, Foli A, Maserati R, Seminari E, Alberici F, Walker B, Lisziewicz J: Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters. AIDS Res Hum Retrovir 1999, 15:1333-1338.
15. Rodriguez CG, Vila J, Capurro AF, Maidana MM, Boffo Lissin LD: Combination therapy with hydroxyurea versus without hydroxyurea as first line treatment options for antiretroviral-naïve patients. HIV Clin Trials 2000, 1:1-8.
16. Vila J, Biron F, Nugier F, Vallet T, Peyramond D: 1-Year follow-up of the use of hydroxycarbamide and didanosine in HIV infection. Lancet 1996, 348:203-204.
17. Biron F, Lucht F, Peyramond D, Fresard A, Vallet T, Nugier F, Grange J, Malley S, Hamedi-Sangsari F, Vila J: Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 10:36-40.
18. Hellinger JA, Iwane MK, Smith JJ, Fleishman AN, Torres RA, Schrader S, Perez G, Cohen CJ, Skowron G, Giordano MF, Accetta G, Cooper EC, Frost KR: A randomized study of the safety and antiretroviral activity of hydroxyurea combined with didanosine in persons infected with human immunodeficiency virus type 1. J Infect Dis 2000, 181:540-547.
19. Goujard C, Boue F, Rousseau C, Mamet JP, Antoun Z, Delfrasssy JF: A pilot study evaluating tolerance and efficacy of abacavir (ABC), amprenavir (APV), didanosine (DDI) and hydroxyurea (HU) in pretreated HIV-1 infected adults: CNAF3011. 7th European Conference on Clinical Aspects and Treatment of HIV Infection. Lisbon, Portugal. Poster 461. October 23-27, 1999
20. Arrizabalaga J, Iribarren JA, Pinilla J, Rodriguez-Arrondo FJ, von Wichman MA, Labarga P, Riera M, Aliaga L, Aguirrebengoa K: Prospective, multicenter study of ddI plus hydroxyurea (HU) plus efavirenz (EFV) plus protease inhibitor (PI) salvage therapy. One-year follow-up. Correlation of viral outcome and genotypic mutations. XIII International AIDS Conference, Durban, South Africa. Poster WePeB4164. July 9-14, 2000
21. Johnson V, Delaugerre C, Hazelwood J, Berzins B, Belsey E, Rhodes R, Calvez V, Katlama C, Murphy R, for the International 3d Study Team: Viral resistance results from the international, multicenter, randomized, placebo-controlled, 48-week study of hydroxyurea (HU) or placebo combined with efavirenz (EFV), didanosine (ddI) and stavudine (d4T) in treatment-naive and - experienced patients. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois. Abstract 445. February 4-8, 2001
22. Rutschmann OT, Vernazza PL, Bucher HC, Opravil M, Ledergerber B, Telenti A, Malinverni R, Bernasconi E, Fagard C, Leduc D, Perrin L, Hirschel B, the Swiss HIV Cohort Study: Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort Study. AIDS 2000, 14:2145-2151.
23. Zala C, Salomon H, Ochoa C, Kijak G, Federico A, Perez H, Montaner JSG, Cahn P: Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection. J Acquir Immune Defic Syndr 2002, 29:368-673.
24. Lafeuillade A, Hittinger G, Chadapaud S, Maillefet S, Rieu A, Poggi C: The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations. HIV Clinical Trials 2002, 3:263-271.
25. Lori F, Gallo RC: Hydroxyurea and AIDS: an old drug finds new application? AIDS Res Hum Retrovir 1995, 11:1149-1151.
26. Gibbs MA, Sorensen SJ: Hydroxyurea in the treatment of HIV-1. Ann Pharmacother 2000, 34:89-93.
27. Gonzalez OY, Jovanovich JF, Mayers DL, Musher DM: The lack of therapeutic benefit of adding hydroxyurea to highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr 2002, 30:363-364. Letter
28. Lori F, Pollard R, Shalit P, Blick G, Peterson D, Lisziewicz J: A low hydroxyurea dose (600 mg daily) is found optimal in a randomized, controlled trial (RIGHT 702). XIVth International AIDS Conference, Barcelona, Spain. Abstract TuPeB4465. July 6-12, 2002
29. Romanelli F, Pomeroy C, Smith KM: Hydroxyurea to inhibit human immunodeficiency virus-1 replication. Pharmacotherapy 1999, 19:196-204.
30. Rossero R, Asmuth DM, Grady JJ, McKinsey DS, Green S, Andron L, Pollard RB: Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature. Intl J STD & AIDS 2003, 14:350-355.
31. Zala C, Salomon H, Gun A, Rouleau D, Pampurro S, Perez H, Cahn P, Montaner JSG: A pilot randomized comparative study of stavudine, didanosine, nevirapine with or without hydroxyurea in primary HIV infection. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois. Abstract 399. February 1-5, 1999
32. Youle M, Mocroft A, Johnson M, Tyrer M, Madge S, Dykhoff A, Drinkwater A: Surrogate marker responses to multidrug combinations comprising hydroxyurea, efavirenz, double protease inhibitors, and nucleoside analogues in protease inhibitor failures. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois. Abstract. February 1-5, 1999
33. Moyle GJ, Sadler M: Peripheral neuropathy with nucleoside antiretrovirals. Risk factors, incidence and management. Drug Safety 1998, 19:481-494.
34. Havlir DV, Gilbert PB, Bennett K, Collier AC, Hirschff MS, Tebas P, Adams EM, Wheat LJ, Goodwin D, Schnittman S, Holohan MK, Richman DD, the ACTG 5025 Study Team: Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression. AIDS 2001, 15:1379-1388.
35. Biron F, Ponceau B, Bouhour D, Boibieux A, Verrier B, Peyramond D: Long-term safety and antiretroviral activity of hydroxyurea and didanosine in HIV-infected patients. J Acquir Immune Defic Syndr 2000, 25:329-336.
36. Hervey PS, Perry CM: Abacavir - a review of its clinical potential in patients with HIV infection. Drugs 2000, 60:447-479.
37. Adkins JC, Noble S: Efavirenz. Drugs 1998, 56:1371-1379.
38. Foli A, Benvenuto F, Piccinini G, Bareggi A, Cossarizza A, Lisziewicz J, Lori F: Direct analysis of mitochondrial toxicity of antiretroviral drugs. AIDS 2001, 15:1687-1694.